Publications of Institute of Radiopharmaceutical Cancer Research

42 Publications

2017

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
Albert, S.; Arndt, C.; Feldmann, A.; Bergmann, R.; Bachmann, D.; Koristka, S.; Ludwig, F.; Ziller-Walter, P.; Kegler, A.; Gärtner, S.; Schmitz, M.; Ehninger, A.; Cartellieri, M.; Ehninger, G.; Pietzsch, H.-J.; Pietzsch, J.; Steinbach, J.; Bachmann, M.
Corresponding author: Arndt, C. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
Feldmann, A.; Arndt, C.; Bergmann, R.; Loff, S.; Cartellieri, M.; Bachmann, D.; Aliperta, R.; Hetzenecker, M.; Ludwig, F.; Albert, S.; Ziller-Walter, P.; Kegler, A.; Koristka, S.; Gärtner, S.; Schmitz, M.; Ehninger, A.; Ehninger, G.; Pietzsch, J.; Steinbach, J.; Bachmann, M.
Corresponding author: Koristka, S.
Corresponding author: Bachmann, M.

2016

Switching CAR T cells on and off: A novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M.; Feldmann, A.; Koristka, S.; Arndt, C.; Loff, S.; Ehninger, A.; von Bonin, M.; Bejestani, E. P.; Ehninger, G.; Bachmann, M. P.
Corresponding author: Bachmann, M. P.

Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model.
Ullrich, M.; Bergmann, R.; Peitzsch, M.; Zenker, E.; Cartellieri, M.; Bachmann, M.; Ehrhart-Bornstein, M.; Block, N.; Schally, A.; Eisenhofer, G.; Bornstein, S.; Pietzsch, J.; Ziegler, C.

An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET.
Hofheinz, F.; Bütof, R.; Apostolova, I.; Zöphel, K.; Steffen, I. G.; Amthauer, H.; Kotzerke, J.; Baumann, M.; van den Hoff, J.

2015

Improved Killing of AML Blasts By Dual-Targeting of CD123 and CD33 Via Unitarg a Novel Antibody-Based Modular T Cell Retargeting System
Arndt, C.; Feldmann, A.; Koristka, S.; Cartellieri, M.; von Bonin, M.; Ehninger, A.; Bornhäuser, M.; Ehninger, G.; Bachmann, M. P.
  • BLOOD 126(2015), 2565

Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer.
Hofheinz, F.; Lougovski, A.; Zöphel, K.; Hentschel, M.; Steffen, I. G.; Apostolova, I.; Wedel, F.; Buchert, R.; Baumann, M.; Brenner, W.; Kotzerke, J.; van den Hoff, J.

Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure
Zschaeck, S.; Haase, R.; Abolmaali, N.; Perrin, R.; Stützer, K.; Appold, S.; Steinbach, J.; Kotzerke, J.; Zips, D.; Richter, C.; Gudziol, V.; Krause, M.; Zöphel, K.; Baumann, M.

Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma
Bütof, R.; Hofheinz, F.; Zöphel, K.; Stadelmann, T.; Schmollack, J.; Jentsch, C.; Loeck, S.; Kotzerke, J.; Baumann, M.; van den Hoff, J.

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
Aliperta, R.; Cartellieri, M.; Feldmann, A.; Arndt, C.; Koristka, S.; Michalk, I.; von Bonin, M.; Ehninger, A.; Bachmann, J.; Ehninger, G.; Bornhäuser, M.; Bachmann, M. P.

DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Toepfer, K.; Cartellieri, M.; Michen, S.; Wiedemuth, R.; Mueller, N.; Lindemann, D.; Bachmann, M.; Fuessel, M.; Schackert, G.; Temme, A.

Improving external beam radiotherapy by combination with internal irradiation.
Dietrich, A.; Koi, L.; Zöphel, K.; Sihver, W.; Kotzerke, J.; Baumann, M.; Krause, M.

Tregs activated by bispecific antibodies: Killers or suppressors?
Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Seliger, B.; Ehninger, G.; Bachmann, M. P.

2014

Dual Role of B7 Costimulation in Obesity-Related Nonalcoholic Steatohepatitis and Metabolic Dysregulation
Chatzigeorgiou, A.; Chung, K.-J.; Garcia-Martin, R.; Alexaki, V.-I.; Klotzsche-Von Ameln, A.; Phieler, J.; Sprott, D.; Kanczkowski, W.; Tzanavari, T.; Bdeir, M.; Bergmann, S.; Cartellieri, M.; Bachmann, M.; Nikolakopoulou, P.; Androutsellis-Theotokis, A.; Siegert, G.; Bornstein, S. R.; Muders, M. H.; Boon, L.; Karalis, K. P.; Lutgens, E.; Chavakis, T.

Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells
Arndt, C.; Feldmann, A.; Töpfer, K.; Koristka, S.; Cartellieri, M.; Temme, A.; Ehninger, A.; Ehninger, G.; Bachmann, M.

Proinflammatory human 6-sulfo LacNAc-positive dendritic cells accumulate in intestinal acute graft-versus-host disease
Sommer, U.; Larsson, B.; Tuve, S.; Wehner, R.; Zimmermann, N.; Kramer, M.; Kloß, A.; Günther, C.; Babatz, J.; Schmelz, R.; Brückner, S.; Schetelig, J.; Bornhäuser, M.; Schäkel, K.; Bachmann, M. P.; Aust, D.; Baretton, G.; Schmitz, M.

Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice
Schütze, C.; Bergmann, R.; Brüchner, K.; Mosch, B.; Yaromira, A.; Zips, D.; Hessel, F.; Krause, M.; Thames, H.; Kotzerke, J.; Steinbach, J.; Baumann, M.; Beuthien-Baumann, B.

Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity
Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Töpfer, K.; Michalk, I.; Temme, A.; Ehninger, G.; Bachmann, M.

Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay
Ingargiola, M.; Runge, R.; Heldt, J.-M.; Freudenberg, R.; Steinbach, J.; Cordes, N.; Baumann, M.; Kotzerke, J.; Brockhoff, G.; Kunz-Schughart, Leoni A.

Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro
Eke, I.; Ingargiola, M.; Förster, C.; Kunz-Schughart, L.; Baumann, M.; Runge, R.; Freudenberg, R.; Kotzerke, J.; Heldt, J.; Pietzsch, H.; Steinbach, J.; Cordes, N.

Simultaneous Targeting of Prostate Stem Cell Antigen and Prostate-Specific Membrane Antigen Improves the Killing of Prostate Cancer Cells Using a Novel Modular T Cell-Retargeting System
Arndt, C.; Feldmann, A.; Koristka, S.; Cartellieri, M.; Dimmel, M.; Ehninger, A.; Ehninger, G.; Bachmann, M.

A novel ex vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells
Cartellieri, M.; Koristka, S.; Arndt, C.; Feldmann, A.; Stamova, S.; von Bonin, M.; Töpfer, K.; Krüger, T.; Geib, M.; Michalk, I.; Temme, A.; Bornhäuser, M.; Lindemann, D.; Ehninger, G.; Bachmann, M. P.

Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8
Michalk, I.; Feldmann, A.; Koristka, S.; Arndt, C.; Cartellieri, M.; Ehninger, A.; Ehninger, G.; Bachmann, M. P.

Letter to the editor: Cytotoxic response of human regulatory 1 T cells upon T cell receptor-mediated activation – a 2 matter of purity
Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Töpfer, K.; Michalk, I.; Temme, A.; Ehninger, G.; Bachmann, M.

Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential
Koi, L.; Bergmann, R.; Brüchner, K.; Pietzsch, J.; Pietzsch, H.-J.; Krause, M.; Steinbach, J.; Zips, D.; Baumann, M.

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity
Cartellieri, M.; Arndt, C.; Feldmann, A.; von Bonin, M.; Ewen, E.-M.; Koristka, S.; Michalk, I.; Stamova, S.; Berndt, N.; Gocht, A.; Bornhäuser, M.; Ehninger, G.; Schmitz, M.; Bachmann, M.

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system
Arndt, C.; Feldmann, A.; von Bonin, M.; Cartellieri, M.; Ewen, E.-M.; Koristka, S.; Michalk, I.; Stamova, S.; Berndt, N.; Gocht, A.; Bornhäuser, M.; Ehninger, G.; Schmitz, M.; Bachmann, M.

Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy
Sihver, W.; Pietzsch, J.; Krause, M.; Baumann, M.; Steinbach, J.; Pietzsch, H. J.

Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles
Brüchner, K.; Beyreuther, E.; Baumann, M.; Krause, M.; Oppelt, M.; Pawelke, J.

2013

Inactivation of HNSCC Cells by 90Y-Labeled Cetuximab Strictly Depends on the Number of Induced DNA Double-Strand Breaks
Saker, J.; Kriegs, M.; Zenker, M.; Heldt, J.-M.; Eke, I.; Pietzsch, H.-J.; Grénman, R.; Cordes, N.; Petersen, C.; Baumann, M.; Steinbach, J.; Dikomey, E.; Kasten-Pisula, U.

2012

Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer
Zips, D.; Zöphel, K.; Abolmaali, N.; Perrin, R.; Abramyuk, A.; Haase, R.; Appold, S.; Steinbach, J.; Kotzerke, J.; Baumann, M.

Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation
Ingargiola, M.; Dittfeld, C.; Runge, R.; Zenker, M.; Heldt, J.-M.; Steinbach, J.; Cordes, N.; Baumann, M.; Kotzerke, J.; Kunz-Schughart, L.

Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro
Saki, M.; Toulany, M.; Sihver, W.; Zenker, M.; Heldt, J.-M.; Mosch, B.; Pietzsch, H.-J.; Baumann, M.; Steinbach, J.; Rodemann, H. P.

2011

Zwei oder vier Stunden [18F]FMISO-PET in Kopf-Hals-Karzinomen: Wann ist der Bildkontrast am höchsten?
Abolmaali, N.; Haase, R.; Koch, A.; Zips, D.; Steinbach, J.; Baumann, M.; Kotzerke, J.; Zöphel, K.

2009

Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation
Bruechner, K.; Bergmann, R.; Santiago, A.; Mosch, B.; Yaromina, A.; Hessel, F.; Hofheinz, F.; van den Hoff, J.; Baumann, M.; Beuthien-Baumann, B.

2008

Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham, C.; Zips, D.; Poenisch, F.; Evers, C.; Enghardt, W.; Abolmaali, N.; Zoephel, K.; Appold, S.; Hoelscher, T.; Steinbach, J.; Kotzerke, J.; Herrmann, T.; Baumann, M.

PET in der Strahlentherapie: Perspektiven / PET in Radiation Oncology - Perspectives
Baumann, M.; Beuthien-Baumann, B.; Zips, D.

2007

Experimental Evaluation of Functional Imaging for Radiotherapy
Zips, D.; Yaromina, A.; Schütze, C.; Wüllrich, K.; Krause, M.; Krause, M.; Hessel, F.; Eicheler, W.; Dörfler, A.; Brüchner, K.; Menegakis, A.; Zhou, X.; Bergmann, R.; van den Hoff, J.; Beuthien-Baumann, B.; Baumann, M.

Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice
Schütze, C.; Bergmann, R.; Yaromina, A.; Hessel, F.; Kotzerke, J.; Steinbach, J.; Baumann, M.; Beuthien-Baumann, B.

2004

Effect of the hypoxic cell sensitizer isometronidazole on local control of two human Squamous Cell Carcinomas after fractionated irradiation.
Schreiber, A.; Krause, M.; Zips, D.; Dörfler, A.; Richter, K.; Vettermann, S.; Petersen, C.; Beuthien-Baumann, B.; Thümmler, D.; Baumann, M.
  • Strahlentherapie und Onkologie 180(2004), 1196-1201

Mikromilieu und Hypoxie im Bild
Baumann, M.; Krause, M.; Eicheler, W.; Petersen, C.; Zips, D.; Beuthien-Baumann, B.; Kotzerke, J.; Laniadao, M.; Herrmann, T.
  • Nova Acta Leopoldina NF 89, Nr. 337 (2004) 119-125

2002

Distribution of 16alpha-[18F]fluoro-estradiol-3,17beta-disulfamate (FESDS) in rats, tumour-bearing mice and piglets
Brust, P.; Rodig, H.; Römer, J.; Kasch, H.; Bergmann, R.; Füchtner, F.; Zips, D.; Baumann, M.; Steinbach, J.; Johannsen, B.
  • Applied Radiation and Isotopes 57 (2002) 687-695